Wang Huiyi, Lei Changhui, Liu Liwen
Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound, Xijing Hospital, Airforce Military Medical University, Xi'an, Shannxi 710032, China.
Eur Heart J Case Rep. 2024 Mar 20;8(4):ytae145. doi: 10.1093/ehjcr/ytae145. eCollection 2024 Apr.
Some patients with hypertrophic cardiomyopathy (HCM) re-occur with drug-refractory symptoms but are not eligible for re-operation after the Morrow procedure. Traditional treatment options are limited. We present the first case of the use of ultrasound-guided percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) for the treatment of a patient with HCM combined with congenital anatomically corrected malposition of the great arteries (MGA) after Morrow procedure.
A 61-year-old male patient with congenital MGA, who had been treated with the Morrow procedure for HCM, had worsening symptoms in recent years that were difficult to control medically. He was diagnosed with occult obstructive HCM by stress echocardiography. After multi-disciplinary discussion, this patient was treated with PIMSRA. The post-operative clinical outcome was remarkable, with a significant decrease in septal thickness and disappearance of the left anterior branch conduction block.
Percutaneous intramyocardial septal radiofrequency ablation is feasible and can be one of the options for the treatment of patients with HCM, especially those who cannot choose Morrow procedure. However, it still needs a large sample of clinical trials to validate its clinical effectiveness.
一些肥厚型心肌病(HCM)患者会再次出现药物难治性症状,但在接受Morrow手术后不适合再次手术。传统治疗选择有限。我们报告首例使用超声引导下经皮心肌内间隔射频消融术(PIMSRA)治疗一名Morrow手术后合并先天性大动脉解剖矫正型转位(MGA)的HCM患者。
一名61岁先天性MGA男性患者,曾接受Morrow手术治疗HCM,近年来症状加重,药物难以控制。经负荷超声心动图诊断为隐匿性梗阻性HCM。经过多学科讨论,该患者接受了PIMSRA治疗。术后临床效果显著,间隔厚度显著降低,左前分支传导阻滞消失。
经皮心肌内间隔射频消融术是可行的,可作为治疗HCM患者的选择之一,尤其是那些无法选择Morrow手术的患者。然而,仍需要大量临床试验来验证其临床疗效。